24Oct 2023
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease

Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease

A recent multicenter trial compared the long-term effectiveness and safety of rosuvastatin and atorvastatin treatments in 4400 adults with coronary artery disease. Over 3 years, both groups experienced similar rates (8.7% rosuvastatin, 8.2% atorvastatin) of all-cause death, MI, stroke, or coronary revascularization. While rosuvastatin lowered LDL cholesterol levels more effectively, it also led to a higher risk of new-onset diabetes (7.2vs. 5.3%) and cataract surgery (2.5vs. 1.5%) than atorvastatin. Other safety outcomes did not significantly differ. The study suggests comparable efficacy in major cardiovascular outcomes between the two drugs but highlights differences in side effects, providing valuable insights for treatment decisions in coronary artery disease patients.

  • #general medicine

Like

Save

Share